DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20171498

A clinical study to determine metformin as a cause of serum vitamin B12 decrease and effect of combination of metformin and mecobalamin on serum vitamin B12 levels in type 2 diabetics

Mayuresh D. Kiran, Bhagyashree N. Naik

Abstract


Background: Several evidences show metformin decreases vitamin B12. Diabetics are also at the risk of developing neuropathy which is treated with vitamin B12. metformin being initial therapy for diabetic patients, it becomes all the more important to know the extent of this decrease. The study was designed with the objective to compare the levels of vitamin B12 in patients on metformin vis-à-vis on antidiabetic drugs other than metformin and to evaluate the increase in vitamin B12 levels after prescribing a combination of metformin and mecobalamin, in T2DM patients.

Methods: Of 500 enrolled, 321 patients completed the study for duration of 6 months, divided in two periods of 3 months each. At the end first period of 3 months the vitamin B12 levels were compared form Metformin vs. that of other antidiabetics. In second period of 3 months a combination of metformin and mecobalamin was given instead of plain metformin and vitamin B12 levels were repeated at the end of this period.

Results: There was reduction in vitamin B12 levels with metformin with levels of 272.5pg/ml compared to 714.6pg/ml with other antidiabetics at the end of first period. The levels increased from 272.5pg/ml to 615.9 pg/ml at the end of second period after receiving the combination of metformin and mecobalamin.

Conclusions: T2DM patients being treated with metformin had a greater risk of reduction in vitamin B12 levels and addition of vitamin B12 in the form of mecobalamin would decrease the reduction in vitamin B12 levels associated with Metformin therapy.


Keywords


Diabetes, Metformin, Mecobalamin, Vitamin B12

Full Text:

PDF

References


International Diabetes Federation. IDF Diabetic Atlas. 7th Ed. Brussels, Belgium: International Diabetes Federation; 2015.

de Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D et al. Long term treatment with Metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.

Pandey AK, Pandey D, and Pandit A. Obesity and Lipid Profile Study in Type 2 Diabetes Patients with Auditory and Reaction Time Deficits and Non-diabetic Control Subjects. Adv Diab Metab. 2017:5;1:1-5.

Shanik MH, Xu Y, Škrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia. Diabetes Care. 2008;31(2):262-8.

Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 2006;49(8):1711-21.

Hermansen K, Mortensen LS, Hermansen M. Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vascular Health and Risk Management. 2008;4(3):561.

Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJM, et al. Long-term effects of Metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616-25.

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2009;162(2):193-212.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).1998;352:854-65.

Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM Risk factors of vitamin B12 deficiency in patients receiving Metformin. Arch Intern Med. 2006;166:1975-9.

Pflipsen MC, Oh RC, Saguil A. The prevalence of vitamin B (12) deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med. 2009;22(5):528-34.

Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP. Association of biochemical B12 deficiency with Metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, Diabetes Care. 2012;35(2):327-33.

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2009;162(2):193-212.

Liu KW, Dai LK, Jean W. Metformin-related vitamin B12 deficiency. Age and Ageing. 2006;35(2):200-1.

Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non–insulin-dependent diabetes mellitus. Arterioscler Thrombo Vascular Biol. 1998;18(1):133-8.

Liu Q, Li S, Quan H, Li J. Vitamin B 12 status in Metformin treated patients: systematic review. PloS one. 2014;9(6):100379.

Kibirige D, Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? J Diab Metab Disord. 2013;12(1):17.

Duby JJ, Campbell RK, Setter SM, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health-Syst Pharmacy. 2004;61(2):160-73.

Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circulation research. 2010;107(9):1058-70.

Ide H, Fujiya S, Asanuma Y, Tsuji M, Sakai H, Agishi Y. Clinical usefulness of intrathecal injection of methylcobalamin in patients with diabetic neuropathy. Clinical therapeutics. 1986;9(2):183-92.

Hairyan JIA., Haorming and Dong. Effects of methylcobalamin on diabetic peripheral neuropathy: a systematic review. Chinese J Evidence Based Medicine. 2005;5(8).

Mizukami H, Ogasawara S, Yamagishi SI, Takahashi K, Yagihashi S. Methylcobalamin effects on diabetic neuropathy and nerve protein kinase C in rats. European J Clini Investi. 2011;41(4):442-50.

Carmel R, Green R, Rosenblatt DS, Watkins D. Update on cobalamin, folate, and homocysteine. ASH Education Program Book. 2003;2003(1):62-81.

Herrmann W, Schorr H, Obeid R, Geisel J. Vitamin B-12 status, particularly holotranscobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians. Am J Clin Nutr. 2003;78(1):131-6.

Wile DJ, Toth C. Association of Metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010;33(1):156-61.

Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by Metformin. Diabetes Care. 2000;23:1227-31.

Wulffele MG. Effects of short-term treatment with Metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Internal Medicine. 2003;254:455-63.

Hermann LS. Vitamin B12 status of patients treated with Metformin: a cross-sectional cohort study, The Br J Diab Vascu Disease. 2004;4(6).

Damião CP, Rodrigues AO, Pinheiro MF, Cruz Filho RA, Cardoso GP, et al. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using Metformin: a cross-sectional study. Sao Paulo Medic J. 2016;134(6):473-9.

Qureshi SA, Ainsworth A, Winocour PH. Metformin therapy and assessment for vitamin B12 deficiency: is it necessary? Prac Diab. 2011;28(7):302-4.